According to the SURMOUNT-1 clinical trial, patients using tirzepatide at the highest dose (15 mg weekly) experienced up to 22.5% total body weight loss over 72 weeksgreater than what is typically seen with semaglutide GLP-1
307,413 In terms of apoptosis inhibition, GLP-1 activates the PI3K/Akt signaling pathway, enhances the expression of the anti-apoptotic protein Bcl-2, and inhibits the activation of caspase family proteins, reducing cell apoptosis
When weight reduction exceeds approximately 1.5 kg per week during early therapy, clinicians should remain alert
There are about 250,000 bariatric surgeries performed each year in the US, and 15% of these are revisions of prior procedures
More significant weight loss and body composition improvements typically occur over the course of several months with consistent therapy and lifestyle adjustments